Rif S El-Mallakh1, Henry David Abraham. 1. Mood Disorders Research Program, Department of Psychiatry and Behavioral Sciences, University of Louisville School of Medicine, Louisville, KY 40202, USA. rselma01@louisville.edu
Abstract
BACKGROUND: 3,4-Methylenedioxymethamphetamine (MDMA or Ecstasy) is a synthetic amphetamine analogue that is recreationally used to obtain a psychological effect of enhanced affiliative emotional response. Its use in Western countries appears to be increasing, particularly among young individuals. METHODS: Pertinent basic and clinical literature is critically reviewed. RESULTS: A significant body of literature suggests that the patterns of MDMA use differ from traditional drugs of abuse, with relatively uncommon dependence and escalation of dosage. Nonetheless, MDMA is also neurotoxic with significant deleterious effects on serotonergic neurons, memory, and mood. Despite this, there is a dearth of treatment strategies for both acute intoxication and consequences of longer term use. CONCLUSIONS: MDMA is an important drug of abuse that has a wide range of adverse consequences.
BACKGROUND:3,4-Methylenedioxymethamphetamine (MDMA or Ecstasy) is a synthetic amphetamine analogue that is recreationally used to obtain a psychological effect of enhanced affiliative emotional response. Its use in Western countries appears to be increasing, particularly among young individuals. METHODS: Pertinent basic and clinical literature is critically reviewed. RESULTS: A significant body of literature suggests that the patterns of MDMA use differ from traditional drugs of abuse, with relatively uncommon dependence and escalation of dosage. Nonetheless, MDMA is also neurotoxic with significant deleterious effects on serotonergic neurons, memory, and mood. Despite this, there is a dearth of treatment strategies for both acute intoxication and consequences of longer term use. CONCLUSIONS:MDMA is an important drug of abuse that has a wide range of adverse consequences.
Authors: J Rouine; M E Kelly; C Jennings-Murphy; P Duffy; I Gorman; S Gormley; C M Kerskens; Andrew Harkin Journal: Psychopharmacology (Berl) Date: 2014-11-01 Impact factor: 4.530
Authors: Una D McCann; Zsolt Szabo; Melin Vranesic; Michael Palermo; William B Mathews; Hayden T Ravert; Robert F Dannals; George A Ricaurte Journal: Psychopharmacology (Berl) Date: 2008-07-27 Impact factor: 4.530
Authors: Una D McCann; Robert R Edwards; Michael T Smith; Kristen Kelley; Michael Wilson; Francis Sgambati; George Ricaurte Journal: Psychopharmacology (Berl) Date: 2011-05-21 Impact factor: 4.530
Authors: Thelma Schilt; Anneke E Goudriaan; Maarten W Koeter; Wim van den Brink; Ben Schmand Journal: Psychopharmacology (Berl) Date: 2008-11-20 Impact factor: 4.530